Piper Jaffray Reports Infinity Initiated Studies In Pancreatic Cancer And Chondrosarcoma

According to Piper Jaffray, Infinity Pharmaceuticals (NASDAQ: INFI) has initiated Phase II studies in pancreatic cancer and chondrosarcoma.

Piper Jaffray reported that it is attending the American Association for Cancer Research (AACR) meeting in Orlando. “We are sensing increased excitement around oral Hedgehog inhibitor IPI-926, on which Infinity will report Phase Ib pancreatic cancer data at ASCO in June. Infinity also presented preclinical data on oral HSP-90 inhibitor IPI-493, which is currently in 2 Phase I studies.”

Infinity Pharmaceuticals closed yesterday at $5.90.